All News

American Cancer Society's annual report shows 1.5 million deaths averted over the past two decades, as well as a jump in survivorship numbers.

As a lung cancer researcher and medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Wash., Howard L. "Jack" West has made communicating with oncology specialists and patients part of his professional mission.

Caregivers walk alongside cancer patients through every step of the journey.

A spouse describes his wife's arrival in Cancerland

When was your last truly remarkable New Year's Eve?

It's hard to believe that 2014 is but a memory. What a unique year to have experienced....filled with the

One-third of men over 70 years of age who undergo radical prostatectomy for prostate cancer and then experience biochemical recurrence have no need for salvage treatment, according to a recent study.

The FDA has updated the label for Gazyva (obinutuzumab) plus chlorambucil to include data from stage 2 of the phase 3 CLL11 study, which detailed an improvement in progression-free survival as a frontline treatment for patients with chronic lymphocytic leukemia.

As I count my many blessings, my wish for you is that you are able to hold fast to the moment and breathe in all that you have, all that is dear to you now and that you, too, will fill your stockings with the presence and love of the moment. Wishing you all a very Merry Christmas!

The mental challenges of having stage 4 breast cancer are just as overwhelming as the physical ones.

Sometimes a break from routine can remind us why we're fighting to live

The PD-1 inhibitor Opdivo (nivolumab) was granted accelerated approval for patients with unresectable or metastatic melanoma following treatment with Yervoy (ipilimumab) or a BRAF inhibitor.

The mental noise that comes with cancer is deafening. Taking cancer time-outs can quiet your anxiety.

Gather together all of your ingredients and whip up something delicious just in time for the holidays.

The Food and Drug Administration approves Lynparza (olaparib) for the treatment of women with BRCA-positive advanced ovarian cancer.

Two HER2-targeting regimens anchored by Kadcyla (T-DM1) failed to outperform the standard strategy of Herceptin plus chemotherapy in women newly diagnosed with advanced HER2-positive breast cancer.

The addition of Avastin (bevacizumab) to standard neoadjuvant chemotherapy significantly improved pathologic complete response rates in women with basal-like breast cancer compared with non-basal-like subtypes.

Learning to cope with a cancer diagnosis is an ongoing process. Coming face to face with death forces one to reexamine what is really important.

The Food and Drug Administration has approved Somatuline Depot (lanreotide) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), based on findings from the phase 3 CLARINET study.

Faslodex (fulvestrant) improved overall survival by nearly six months compared with anastrozole as initial hormone therapy for postmenopausal women with estrogen receptor-positive advanced breast cancer, according to findings from the phase 2 FIRST trial.

The FDA has approved Cyramza (ramucirumab) in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer whose tumor has progressed during or following treatment with platinum-based chemotherapy.

Dr. Mary Claire King's search for the breast cancer gene spanned 20 years.

I talked about chemotherapy and the kindness of nurses who helped me to make those early days of the treatment chair easier: the value of listening, the importance of a smile or touch, the validation of my fears and hopes.

Findings from a long-term analysis of the Women's Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptor–negative breast cancers were reduced by up to 54 percent when they followed a program to reduce their dietary fat intake, which could provide benefit for patients with triple-negative breast cancer.

There is comfort in having a simple cause and effect. The unknown can be difficult to accept.

Debu Tripathy,editor-in-chief of CURE magazine, explains the importance of chemotherapy studies presented at the 2014 San Antonio Breast Cancer Symposium, including new data on the impact of side effects.

Karen Durham never expected to be speaking on behalf of the Metastatic Breast Cancer Alliance

The PD-1 inhibitor Keytruda (pembrolizumab) has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer (TNBC).

When 34-year-old Jen Levinson was diagnosed with stage 2 breast cancer in 2000, the breast cancer world gained a powerful advocate -- but it wasn't Jen, it was her mother.

Abraxane (nab-paclitaxel) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk, early breast cancer, according to results presented at the 2014 San Antonio Breast Cancer Symposium.